Establishes a mandated window of five business days for both Medicaid and private insurers to respond to pre-authorization claims for testing and/or treatments made by physicians on behalf of oncology patients.
Summary
Bill A01462 aims to amend the insurance law in New York by establishing a mandated response time of five business days for both Medicaid and private insurers to respond to pre-authorization claims submitted by physicians for oncology patients. This bill is designed to ensure timely access to necessary testing and treatments for patients diagnosed with cancer, thereby potentially improving patient outcomes by reducing delays in care.
Impact
If enacted, this bill will significantly alter the current procedures regarding pre-authorization claims for oncology treatments. Insurers will be required to respond within the specified timeframe, and failure to do so will allow physicians to proceed with the necessary medical procedures without prior approval, placing the financial responsibility on the insurers. This change aims to enhance patient care and streamline the process for healthcare providers, particularly in urgent situations where timely treatment is critical.
Sentiment
The sentiment surrounding Bill A01462 appears to be supportive, particularly among healthcare professionals and advocates for oncology patients who emphasize the importance of timely access to care. However, there may be concerns from insurance companies regarding the implications of mandated response times and the potential for increased costs associated with delayed authorizations.
Contention
Notable points of contention may arise from insurance companies who could argue that the mandated response time may not account for the complexities of certain cases, potentially leading to rushed decisions. Conversely, proponents of the bill, including oncologists and patient advocacy groups, argue that the urgency of cancer treatment justifies the need for such regulations to avoid detrimental delays in patient care.
Same As
Establishes a mandated window of five business days for both Medicaid and private insurers to respond to pre-authorization claims for testing and/or treatments made by physicians on behalf of oncology patients.
Establishes a mandated window of five business days for both Medicaid and private insurers to respond to pre-authorization claims for testing and/or treatments made by physicians on behalf of oncology patients.
Relates to excepting situations where a physician or other licensed health care provider is authorized to dispense certain medications and is practicing medicine in the oncology setting and is dispensing oncology drugs or drugs related to an approved course of treatment used to manage symptoms related to cancer or cancer therapies.
Relates to excepting situations where a physician or other licensed health care provider is authorized to dispense certain medications and is practicing medicine in the oncology setting and is dispensing oncology drugs or drugs related to an approved course of treatment used to manage symptoms related to cancer or cancer therapies.
Includes certain willful representations made by physicians, physician's assistants, and specialist's assistants to patients and clients, or relating to patients' and clients' private health information, as professional misconduct.
Includes certain willful representations made by physicians, physician's assistants, and specialist's assistants to patients and clients, or relating to patients' and clients' private health information, as professional misconduct.